How should a patient on prasugrel presenting with a severe thunderclap headache be managed?

Management of Severe Thunderclap Headache in a Patient on Prasugrel

A patient on prasugrel presenting with severe thunderclap headache requires immediate non-contrast head CT to rule out subarachnoid hemorrhage (SAH), and if intracranial hemorrhage is confirmed, prasugrel must be discontinued immediately with consideration of platelet transfusion at double the standard dose before urgent neurosurgical intervention. 1, 2, 3

Immediate Diagnostic Evaluation

First-Line Imaging (Within 6 Hours)

• Obtain immediate non-contrast head CT on a high-quality scanner interpreted by a board-certified neuroradiologist, which has 98.7% sensitivity for detecting SAH when performed within 6 hours of symptom onset 1
• CT demonstrates 98% sensitivity and 99% specificity for acute SAH overall, making it the critical first diagnostic step 1
• Critical pitfall: CT sensitivity declines sharply after 6 hours (93% at 24 hours, 57-85% at 6 days), so timing is essential 1

If CT is Negative or Nondiagnostic (>6 Hours from Onset)

• Lumbar puncture is mandatory when initial CT is negative or nondiagnostic AND symptom onset occurred >6 hours earlier 1
• LP should be performed at least 6-12 hours after headache onset to allow xanthochromia to develop 1
• Spectrophotometric analysis of CSF for xanthochromia provides approximately 100% sensitivity and 95% specificity for ruptured aneurysms 1
• Alternative: CT angiography serves as a reasonable alternative to LP when clinical suspicion remains high, offering 97% sensitivity for cerebrovascular pathology 1

Risk Stratification

• Apply the Ottawa SAH Rule criteria: age ≥40 years, neck pain/stiffness, witnessed loss of consciousness, onset during exertion, or limited neck flexion on examination 1
• The Ottawa SAH Rule has 100% sensitivity but only 15% specificity, effectively identifying all high-risk patients requiring further workup 1

Management Based on CT Findings

If Intracranial Hemorrhage is Confirmed

Antiplatelet Reversal Strategy:

• Discontinue prasugrel immediately 2, 3
• Administer platelet transfusion at double the standard dose used for aspirin reversal (>1.0-1.4 × 10¹¹ platelets per 10 kg body weight) 2
• Early platelet transfusion (within 12 hours) is associated with less hematoma expansion in intracranial hemorrhage 2
• Do NOT use recombinant Factor VIIa (rFVIIa) for prasugrel reversal—it shows no hemostatic benefit and may induce arterial thrombosis 2

Blood Pressure Management:

• Control blood pressure with a titratable antihypertensive agent to minimize rebleeding risk while preserving cerebral perfusion pressure 1
• This is critical between symptom onset and definitive aneurysm obliteration 1

Urgent Neurosurgical Consultation:

• Obtain immediate neurosurgical consultation for definitive treatment (surgical clipping or endovascular coiling) 1
• Early aneurysm rebleeding carries very poor prognosis; rebleeding increases odds of poor outcome approximately 10-fold 1
• Early clipping or coiling performed as soon as feasible significantly lowers rebleeding likelihood 1

Neuroprotective Therapy:

• Administer oral nimodipine to all patients with confirmed aneurysmal SAH to improve neurological outcomes 1

Mechanical Hemostasis:

• Prioritize mechanical hemostasis (surgery, endoscopy, embolization, tamponade) over drug discontinuation alone 2
• Administer tranexamic acid early in severe bleeding—it is safe and effective without increased thrombotic risk 2

If CT is Negative

Further Vascular Imaging:

• Obtain brain MRI with susceptibility-weighted imaging (SWI) and vascular sequences (CTA or MRA) to evaluate for reversible cerebral vasoconstriction syndrome, arterial dissection, cerebral venous thrombosis, and other vascular pathologies 1
• FLAIR and SWI/GRE sequences detect acute SAH with 50-94% sensitivity 1
• Consider cervical artery dissection, which presents with thunderclap headache in up to 20% of cases and may be associated with Horner syndrome 1

Digital Subtraction Angiography:

• When SAH is confirmed, DSA with 3-dimensional rotational angiography is indicated to precisely locate aneurysms and guide definitive treatment 1
• DSA is more sensitive than CTA/MRA for small-vessel disease and arterial dissection 1

Special Considerations for Prasugrel Patients

High-Risk Features for Bleeding

• Body weight <60 kg: These patients have increased exposure to prasugrel's active metabolite and higher bleeding risk 2, 3
• Age ≥75 years: Prasugrel is generally not recommended due to increased risk of fatal and intracranial bleeding 2, 3
• Concomitant medications: Warfarin, heparin, fibrinolytic therapy, or chronic NSAIDs increase bleeding risk 3

Timing Considerations

• Prasugrel causes irreversible platelet inhibition lasting the platelet lifespan (7-10 days) 2
• For planned intracranial surgery, prasugrel should be discontinued at least 9 days before the procedure (7 days for non-intracranial surgery plus 2 additional days) 2
• However, in the emergency setting with confirmed intracranial hemorrhage, do not delay neurosurgical intervention waiting for prasugrel effects to dissipate—use platelet transfusion instead 2

Critical Pitfalls to Avoid

• Never rely on CT alone beyond 6 hours after symptom onset—lumbar puncture becomes mandatory when clinical suspicion remains high 1
• Never perform LP before 6 hours after headache onset, as this may miss xanthochromia and lead to false-negative results 1
• Never fail to obtain initial non-contrast head CT—this is the most frequent diagnostic error, contributing to a 12% misdiagnosis rate 1
• Misdiagnosis of SAH is associated with an almost 4-fold higher risk of death or disability at one year 1
• Never discontinue prasugrel in the first few weeks after ACS unless absolutely necessary for life-threatening bleeding, as this increases risk of subsequent cardiovascular events 3

Transfer Considerations

• Hospitals treating fewer than 10 aneurysmal SAH cases per year should consider early transfer to high-volume centers (≥35 cases/year) with experienced cerebrovascular surgeons, endovascular specialists, and multidisciplinary neuro-intensive care teams 1